These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16247341)

  • 21. Tipranavir: a new protease inhibitor for the pediatric population.
    Courter JD; Girotto JE; Salazar JC
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):797-803. PubMed ID: 19053893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tipranavir demonstrates potent and durable treatment response in HIV-positive women.
    AIDS Patient Care STDS; 2007 Aug; 21(8):602-3. PubMed ID: 17907309
    [No Abstract]   [Full Text] [Related]  

  • 23. New antiretroviral may help failing PI regimens.
    Markowitz M
    AIDS Alert; 2001 Sep; 16(9):116-7. PubMed ID: 11547495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SPRING: a new trial to evaluate tipranavir in heterogeneous treatment-experienced HIV populations.
    Vispo E
    AIDS Rev; 2007; 9(2):126-7. PubMed ID: 17695065
    [No Abstract]   [Full Text] [Related]  

  • 25. Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies.
    Boffito M; Maitland D; Pozniak A
    J Clin Pharmacol; 2006 Feb; 46(2):130-9. PubMed ID: 16432264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tipranavir: a novel second-generation nonpeptidic protease inhibitor.
    Kandula VR; Khanlou H; Farthing C
    Expert Rev Anti Infect Ther; 2005 Feb; 3(1):9-21. PubMed ID: 15757454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tipranavir: the first nonpeptidic protease inhibitor.
    Cheonis N
    BETA; 2004; 16(2):15-7. PubMed ID: 15104065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Some existing drugs work on resistant HIV.
    AIDS Alert; 2000 Jan; 15(1):10-2. PubMed ID: 11366357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. European Commission grants full approval for Aptivus.
    AIDS Patient Care STDS; 2008 May; 22(5):438. PubMed ID: 18521974
    [No Abstract]   [Full Text] [Related]  

  • 30. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.
    Raffi F; Battegay M; Rusconi S; Opravil M; Blick G; Steigbigel RT; Kraft M; Neubacher D; Sabo JP
    AIDS; 2007 Sep; 21(14):1977-80. PubMed ID: 17721109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
    Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
    Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
    González de Requena D; Calcagno A; Bonora S; Ladetto L; D'Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G
    AIDS; 2006 Oct; 20(15):1977-9. PubMed ID: 16988521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boehringer drug for resistant HIV approved.
    AIDS Read; 2005 Aug; 15(8):379, 391. PubMed ID: 16110551
    [No Abstract]   [Full Text] [Related]  

  • 34. Tipranavir.
    Temesgen Z; Cainelli F; Vento S
    Drugs Today (Barc); 2005 Nov; 41(11):711-20. PubMed ID: 16395412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tipranavir: a review of its use in the management of HIV infection.
    Orman JS; Perry CM
    Drugs; 2008; 68(10):1435-63. PubMed ID: 18578560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New treatment options for HIV-infected patients].
    Wehr A
    Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
    [No Abstract]   [Full Text] [Related]  

  • 37. Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men.
    Walmsley SL; Squires K; Weiss L; Easterbrook P; Orani A; Kraft M; Scherer J
    AIDS; 2009 Jan; 23(3):429-31. PubMed ID: 19114862
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-HIV agents. Tipranavir for treatment-experienced PHAs.
    TreatmentUpdate; 2007 Jan; 19(1):8. PubMed ID: 17390481
    [No Abstract]   [Full Text] [Related]  

  • 39. New hope in tipranavir. New Boehringer-Ingelheim protease inhibitor may succeed where others fall short.
    Rodriguez E
    Posit Living; 2001; 10(6):15. PubMed ID: 11702749
    [No Abstract]   [Full Text] [Related]  

  • 40. Salvage therapy update.
    Emery C
    Surviv News (Atlanta Ga); 2005; 16(6):8. PubMed ID: 16388538
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.